Filter Results:
(347)
Show Results For
- All HBS Web
(586)
- People (4)
- News (151)
- Research (347)
- Events (2)
- Multimedia (4)
- Faculty Publications (172)
Show Results For
- All HBS Web
(586)
- People (4)
- News (151)
- Research (347)
- Events (2)
- Multimedia (4)
- Faculty Publications (172)
Sort by
- 14 Apr 2021
- Research & Ideas
The High Cost of the Slow COVID Vaccine Rollout
the United States, the Federal Drug Administration this week advised states to pause the use of the Johnson & Johnson vaccine after six women developed a rare blood-clotting disorder, raising new... View Details
- 08 Apr 2009
- Research & Ideas
Clayton Christensen on Disrupting Health Care
An acclaimed author and expert on the development and commercialization of technological and business innovation, HBS professor Clayton Christensen has written a new book aimed at changing our national conversation about health care. In... View Details
- 27 Sep 2011
- First Look
First Look: September 27
and provocative, this book is an essential resource for all teams seeking to strengthen their innovative prowess. Publisher's link: http://hbr.org/product/the-innovator-s-dna-mastering-the-five-skills-of-d/an/14946-HBK-ENG?referral=00215&cm_mmc=email-_-news View Details
Keywords: Sean Silverthorne
- 01 May 2007
- First Look
First Look: May 1, 2007
face major challenges including headline-grabbing litigation, imminent patent expirations, new technologies, rising drug development costs, generic drug substitution,... View Details
Keywords: Sean Silverthorne
- 23 Apr 2014
- HBS Case
Are Electronic Cigarettes a Public Good or Health Hazard?
Drug Administration is proposing the first federal oversight of the product. The very fact users could control the amount of nicotine they ingested led to worry that e-cigarettes would cause smokers to take in more nicotine, rather than... View Details
- 31 May 2016
- First Look
May 31, 2016
additively separable in its state variables, leading to conquering the curse of dimensionality and the opportunity to manage the supply chain using independently acting managers. We develop conditions under which myopic policies are... View Details
Keywords: Sean Silverthorne
- 21 Jul 2015
- First Look
First Look: July 21, 2015
https://www.hbs.edu/faculty/Pages/item.aspx?num=49375 Enabling Versus Controlling-Online Appendix By: Hagiu, Andrei, and Julian Wright Abstract—No abstract available. Download working paper: https://www.hbs.edu/faculty/Pages/item.aspx?num=49378 Mobile Money... View Details
Keywords: Sean Silverthorne
- 03 Jul 2012
- Research & Ideas
HBS Faculty on Supreme Court Health Care Ruling
required to support them. Further, government payment for sick people's health care expenses will diminish the massive venture capital investment needed for developing genomically-derived therapies. We stand at the brink of a revolution... View Details
- 02 Jan 2020
- Op-Ed
Medicare for All or Public Option: Can Either Heal Health Care?
The United States has serious health care problems: More than 27 million uninsured people, costs that are growing faster than income, and a staggering $37 trillion of unfunded liabilities in the Medicare program. Perhaps most alarming: The US ranks lowest among View Details
- 16 Oct 2013
- Op-Ed
Response to Readers: Combating Climate Change with Nuclear Power and Fracking
recommendations in my mind to improve the pace of nuclear innovation. A clear direction for improvement would be to adopt a Food and Drug Administration-style drug development... View Details
- 05 Jul 2004
- Research & Ideas
Radical Change, Entrepreneurial Opportunity
advantage? It's a conscious strategy to play to their strengths? A: I think that's right. For instance, Polaroid identified digital imaging as an opportunity very early on; in fact, you could argue that its mindset in terms of what the firm was good at enabled it to... View Details
- 30 Mar 2010
- First Look
First Look: March 30
GordonHarvard Business School Case 810-066 In May 2007, Amgen Inc. (Amgen) received disappointing news from the European Medicines Agency (EMEA) that its drug Vectibix, developed to fight metastatic... View Details
Keywords: Sean Silverthorne
- 02 Jul 2001
- Research & Ideas
Ray A. Goldberg
"Transforming Life, Transforming Business: The Life-Science Revolution," a McKinsey Award-winning article he coauthored in the March-April 2000 issue of Harvard Business Review. "As distinctions between food and medicine fade, we will see a proliferation... View Details
- 12 Jul 2006
- Research & Ideas
Competition the Cure for Healthcare
the various actors in the system are not designed around value, nor is competition reinforcing improvements in value. For example, let's take the prescription drug benefit, the big reform of today that everyone is talking about. This is... View Details
- 26 Apr 2004
- Research & Ideas
A Clear Eye for Innovation
organization would have to continue making money in the mature conventional-contacts business while simultaneously producing a stream of breakthroughs. In 1991, Bradley launched six formal development projects, each focused on a... View Details
- 08 Mar 2016
- First Look
March 8, 2016
cultural model and undermine their own positions with inappropriate use of symbolic market-creation actions. Download working paper: https://www.hbs.edu/faculty/Pages/item.aspx?num=50701 Harvard Business School Case 916-026 Express Scripts: Promoting Prescription View Details
Keywords: Sean Silverthorne
- 12 Feb 2019
- First Look
New Research and Ideas, February 12, 2019
trials. As the Group Director of Bristol-Myers Squibb, Carson worked on the drug Aripiprazole, an antipsychotic drug that is more famously known as Abilify, which had been View Details
Keywords: Dina Gerdeman
- 19 Jun 2013
- Research & Ideas
Analyzing Institutions to Solve Big Problems
that marijuana was a popular treatment in the nineteenth century, and the drug was listed in the Dispensatory of the United States by the 1850s. The paper looks at how the Federal Bureau of Narcotics managed not only to illegalize the... View Details
Keywords: by Carmen Nobel & Anna Secino
- 19 Sep 2012
- Research & Ideas
Funding Innovation: Is Your Firm Doing it Wrong?
programs to an investment board comprising both insiders (senior GSK executives) and outsiders (including a venture capitalist and a biotech CEO). After a three-month review period, successful teams are awarded three years worth of investment funding. Because View Details
Keywords: by Carmen Nobel
- 05 Nov 2007
- Research & Ideas
The Changing Face of American Innovation
The contributions made by immigrant scientists and engineers for developing new U.S. technologies have been formidable—but not always well described. What we do know: While the foreign-born account for just over 10 percent of the U.S.... View Details